JP7140781B2 - 化合物、組成物および方法 - Google Patents

化合物、組成物および方法 Download PDF

Info

Publication number
JP7140781B2
JP7140781B2 JP2019563609A JP2019563609A JP7140781B2 JP 7140781 B2 JP7140781 B2 JP 7140781B2 JP 2019563609 A JP2019563609 A JP 2019563609A JP 2019563609 A JP2019563609 A JP 2019563609A JP 7140781 B2 JP7140781 B2 JP 7140781B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
disease
heterocyclyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520925A (ja
JP2020520925A5 (enExample
Inventor
ジルジョ・ボナノーミ
アンソニー・エー・エストラーダ
ジアンウェン・エー・フェン
ブライアン・フォックス
チンツァ・マリア・フランチーニ
チェン・フー
コリン・フィリップ・レズリー
マクシム・オシポフ
アナンサ・スダーカール
ザッカリー・ケー・スウィーニー
ハビエル・デ・ビセンテ・フィダルゴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020520925A publication Critical patent/JP2020520925A/ja
Publication of JP2020520925A5 publication Critical patent/JP2020520925A5/ja
Priority to JP2022141824A priority Critical patent/JP2022174180A/ja
Application granted granted Critical
Publication of JP7140781B2 publication Critical patent/JP7140781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019563609A 2017-05-17 2018-05-17 化合物、組成物および方法 Active JP7140781B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022141824A JP2022174180A (ja) 2017-05-17 2022-09-07 化合物、組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507682P 2017-05-17 2017-05-17
US62/507,682 2017-05-17
PCT/US2018/033269 WO2018213634A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022141824A Division JP2022174180A (ja) 2017-05-17 2022-09-07 化合物、組成物および方法

Publications (3)

Publication Number Publication Date
JP2020520925A JP2020520925A (ja) 2020-07-16
JP2020520925A5 JP2020520925A5 (enExample) 2021-07-26
JP7140781B2 true JP7140781B2 (ja) 2022-09-21

Family

ID=64274734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563609A Active JP7140781B2 (ja) 2017-05-17 2018-05-17 化合物、組成物および方法
JP2022141824A Withdrawn JP2022174180A (ja) 2017-05-17 2022-09-07 化合物、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022141824A Withdrawn JP2022174180A (ja) 2017-05-17 2022-09-07 化合物、組成物および方法

Country Status (11)

Country Link
US (2) US11174262B2 (enExample)
EP (1) EP3625234B1 (enExample)
JP (2) JP7140781B2 (enExample)
KR (1) KR102637541B1 (enExample)
CN (1) CN110914275A (enExample)
AU (2) AU2018269745C1 (enExample)
BR (1) BR112019023979A2 (enExample)
CA (1) CA3063938A1 (enExample)
IL (1) IL270505B2 (enExample)
MX (1) MX2019013642A (enExample)
WO (1) WO2018213634A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022174180A (ja) * 2017-05-17 2022-11-22 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552017B1 (en) * 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
WO2022046905A1 (en) * 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
WO2023076133A1 (en) * 2021-10-27 2023-05-04 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof
WO2025045281A2 (zh) * 2023-08-31 2025-03-06 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP2008505976A (ja) 2004-07-12 2008-02-28 アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド テトラペプチド類似体
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP2009544728A (ja) 2006-07-24 2009-12-17 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
JP5178203B2 (ja) 2005-11-24 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２環式シンナミド化合物
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016500691A (ja) 2012-10-22 2016-01-14 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
JP6683712B2 (ja) * 2014-12-24 2020-04-22 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン ネクローシス阻害薬
WO2018213634A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP2008505976A (ja) 2004-07-12 2008-02-28 アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド テトラペプチド類似体
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP5178203B2 (ja) 2005-11-24 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２環式シンナミド化合物
JP2009544728A (ja) 2006-07-24 2009-12-17 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
JP2016500691A (ja) 2012-10-22 2016-01-14 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022174180A (ja) * 2017-05-17 2022-11-22 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法

Also Published As

Publication number Publication date
WO2018213634A1 (en) 2018-11-22
CA3063938A1 (en) 2018-11-22
AU2018269745C1 (en) 2022-06-09
MX2019013642A (es) 2020-07-20
US11174262B2 (en) 2021-11-16
IL270505B2 (en) 2023-09-01
JP2020520925A (ja) 2020-07-16
IL270505A (enExample) 2019-12-31
CN110914275A (zh) 2020-03-24
IL270505B1 (en) 2023-05-01
AU2022202524A1 (en) 2022-05-12
EP3625234A4 (en) 2021-03-10
KR20200006120A (ko) 2020-01-17
US20200079784A1 (en) 2020-03-12
JP2022174180A (ja) 2022-11-22
AU2022202524B2 (en) 2023-10-05
AU2018269745A1 (en) 2019-11-28
EP3625234B1 (en) 2023-09-20
EP3625234A1 (en) 2020-03-25
KR102637541B1 (ko) 2024-02-15
AU2018269745B2 (en) 2022-01-27
US20220024938A1 (en) 2022-01-27
US11851433B2 (en) 2023-12-26
BR112019023979A2 (pt) 2020-06-09

Similar Documents

Publication Publication Date Title
JP2022174180A (ja) 化合物、組成物および方法
CN108602809B (zh) 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
JP7208137B2 (ja) 化合物、組成物および方法
TWI786049B (zh) 化合物、組合物及方法
AU2021206809B2 (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
JP2022520236A (ja) 化合物、組成物、及び、方法
CA3071024A1 (en) Compounds, compositions and methods
CA3072057A1 (en) Small molecule modulators of eukaryotic initiation factor 2b
BR112019023918A2 (pt) Inibidores de quinase e usos dos mesmos
EP4320127A1 (en) Nek7 inhibitors
EP3860975A1 (en) Modulators of hemoglobin for the treatment of sickle cell disease
HK40016450B (en) Compounds useful as ripk1 inhibitors
OA19864A (en) Compounds, compositions, and methods.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220908

R150 Certificate of patent or registration of utility model

Ref document number: 7140781

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250